Surmodics to receive $27 million milestone payment from Abbott Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the
Of patients with chronic limb-threatening ischemia and no revascularization options, 76% avoided amputation after a procedure that delivers oxygenated blood to an ischemic foot via the venous system.
EDEN PRAIRIE, Minn. (BUSINESS WIRE) #InVitroDiagnostic Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fis.
Significant findings from the “BEST-CLI Best Endovascular versus Best Surgical Therapy for Patients with Critical Limb Ischemia” clinical trial were presented Nov. 7 during the American Heart Association Scientific Sessions (AHA2022).